Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics (Nasdaq: BEAM) has published research in The CRISPR Journal detailing the development of Inlaid Base Editors (IBEs), enhancing base editing capabilities. This innovation aims to treat sickle cell disease (SCD) by converting the sickle hemoglobin allele to the benign HbG-Makassar variant, achieving over 70% editing efficiency in patient-derived cells. IBEs provide a broader editing range with reduced off-target effects, solidifying Beam's position as a leader in genetic medicine. The company plans to submit its first investigational new drug application in H2 2021.
Beam Therapeutics (BEAM) reported significant advancements as of March 15, 2021. The company is set to submit its first IND application for BEAM-101 by mid-2021, supported by a $260 million stock investment enhancing its balance sheet. The acquisition of Guide Therapeutics allows for improved gene delivery capabilities. Beam's leadership team expanded with the appointments of Amy Simon as Chief Medical Officer and Kate Walsh to the board. Despite this progress, Beam reported a net loss of $195.9 million for 2020, reflecting ongoing R&D investments of $103.2 million.
Beam Therapeutics (Nasdaq: BEAM) announced the appointment of Amy Simon, M.D. as Chief Medical Officer, effective March 15, 2021. With over 20 years of experience in clinical development, Dr. Simon previously held significant roles at Alnylam Pharmaceuticals, where she led the clinical development of RNAi-based therapies and was key in the approval of GIVLAARI. CEO John Evans highlighted the importance of her expertise as Beam progresses towards its first IND application for BEAM-101 in late 2021. Dr. Simon aims to leverage Beam's pioneering base editing technology to deliver transformative therapies for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) will have its CEO, John Evans, speak at the Barclays 2021 Global Healthcare Conference on March 11, 2021, at 2:25 p.m. ET. The event will be available via a live webcast on the company's investor website, with an archive lasting 60 days post-event. Beam Therapeutics specializes in precision genetic medicines using base editing technology to achieve targeted genomic changes without DNA breaks, aiming to develop therapies for serious diseases.
Beam Therapeutics Inc. (Nasdaq: BEAM) has acquired Guide Therapeutics, Inc. for $120 million in stock, aiming to enhance its gene editing capabilities. This acquisition is expected to expand Beam's reach into new tissues and diseases, leveraging GuideTx's innovative lipid nanoparticle (LNP) technology. An additional $320 million may be paid based on success milestones. The merger is anticipated to accelerate the development of genetic medicines, potentially offering lifelong cures for various diseases.
Beam Therapeutics announced a private placement to sell 2,795,700 shares of common stock to institutional investors, expecting gross proceeds of approximately $260 million at an offering price of $93.00 per share, a 10% discount to the recent average share price. The closing is anticipated on January 21, 2021. Proceeds will support clinical development and strategic partnerships. J.P. Morgan and William Blair are acting as placement agents. The shares will not be registered under the Securities Act but a resale registration will be filed with the SEC.
Beam Therapeutics (Nasdaq: BEAM) has appointed Kate Walsh, President and CEO of Boston Medical Center, to its board of directors. Walsh brings extensive experience in leading healthcare organizations, which is expected to enhance Beam's mission of developing precision genetic medicines through base editing. The company anticipates 2021 to be a pivotal year, with plans for filing its first Investigational New Drug application. Both Walsh and Beam’s leadership express optimism about the potential impact of its innovative treatments on patients with serious diseases.
Beam Therapeutics (Nasdaq: BEAM) will have CEO John Evans presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 11:40 a.m. ET. Investors can access a live webcast on the company’s website, which will also be archived for 60 days. Beam Therapeutics specializes in precision genetic medicines using base editing technology, allowing precise genomic modifications without DNA breaks. Their innovative approach aims to deliver effective therapeutic solutions for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) announced significant findings regarding its base editing technology during the 62nd American Society of Hematology Annual Meeting. Data from the BEAM-101 program showed no off-target editing, supporting a future Investigational New Drug application in H2 2021. The Makassar base editor demonstrated a 50% conversion of the sickle allele to a non-disease variant, with evidence of sustained editing after 16 weeks. These advancements may lead to effective treatments for sickle cell disease, affecting nearly 100,000 Americans.
Summary not available.